Healthcare >> CEO Interviews >> September 13, 2002
AYA JAKOBOVITS, PhD, is Senior Vice President, Technology and Corporate
Development and Chief Scientific Officer at Agensys, Inc. She joined the
company in January 1999 after serving as Director of Discovery Research
and Principal Scientist at Abgenix, Inc., since its founding in 1996.
Dr. Jakobovits was previously at Cell Genesys, Inc., where she served in
a number of positions since 1989, most recently as Director of Molecular
Immunology. She is known for her leadership in developing the XenoMouse_
technology, and its utilization for production of therapeutic fully
human monoclonal antibodies, including ABX-EGF, a fully human antibody
to EGF receptor. Dr. Jakobovits received her PhD in Life Sciences and an
MSc in Chemistry from the Weizmann Institute of Science, Rehovot,
Israel, and her BSc in Chemistry from the Hebrew University in
Jerusalem, Israel. She did her post-doctoral work at the University of
California, San Francisco and Genentech, Inc. Profile
Dr. Jakobovits: Agensys is engaged in the development of novel
therapeutic antibody products in cancer based on its own
